DHEA Versus Placebo in Women With Poor Ovarian Response
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
440 women with expected poor ovarian response undergoing IVF/ICSI (intracytoplasmic sperm
injection) will be randomly divided into 2 groups using computer generated random numbers .
Group 1 ( study group) will receive Dehydroepiandrosterone (DHEA) 25 mg ( DHEA 25mg, Natrol ,
USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle. Group 2 ( control group) will
receive a placebo. Patients included in the study will be subjected to full history taking
and clinical examination. On the second day of menstruation serum FSH, LH, Prolactin and
Oestradiol will be assessed and the antral follicular count (AFC) will be assessed using a
vaginal ultrasound scan. AFC will be defined as the number of follicles measuring 3-10mm.
All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin
(HMG) stimulation until the day of (Human chorionic gonadotrophin (HCG) administration. On
the day of HCG administration, ovarian ultrasound scan will be performed using a transvaginal
probe. Oocytes will be aspirated 34-36 hours after HCG administration. Oocytes will be
fertilized and embryos will be transferred. Both groups will be compared regarding the
proportion of pregnancy.